Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for ImmunityBio, Inc. (IBRX), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-8.87
P/B ratioShare price divided by book value per share.
-8.67
P/S ratioMarket value divided by annual revenue.
55.23
PEG ratioP/E divided by the earnings growth rate.
0.07
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
-11.08
EV / RevenueEnterprise value against annual revenue.
59.68
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-9.82%
Free cash flow yieldFree cash flow as a percentage of market value.
-3.15%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
94.63%
Operating marginRevenue left after operating costs.
-151.88%
Net marginRevenue left after every cost, including tax and interest.
-598.56%
Return on equityProfit as a percentage of shareholders’ equity.
134.99%
Return on assetsProfit as a percentage of total assets.
-157.89%
Return on capital employedOperating profit against the capital the business uses.
-45.63%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
5.72
Quick ratioThe same, excluding inventory.
5.70
Cash ratioCash alone against current liabilities.
1.42
Debt to equityTotal borrowings against shareholders’ equity.
-0.78
Debt to assetsTotal borrowings against total assets.
1.75
Interest coverageHow many times operating profit covers the interest bill.
-3.02
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-0.38
Book value per shareShareholders’ equity divided by shares outstanding.
$-0.83
Shares outstandingShares currently issued.
0
Market capitalisationShare price times shares outstanding.
$8.71B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$9.89B
EmployeesReported headcount.
691
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
ImmunityBio, Inc. (IBRX) statistics — frequently asked questions
What is ImmunityBio, Inc.'s P/E ratio?
ImmunityBio, Inc. (IBRX) trades on a price-to-earnings ratio of -8.87. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is ImmunityBio, Inc.'s return on equity?
ImmunityBio, Inc. (IBRX) reports a return on equity of 134.99%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does ImmunityBio, Inc. carry?
ImmunityBio, Inc. (IBRX) has a debt-to-equity ratio of -0.78, which compares total borrowings with shareholders' equity.
What is ImmunityBio, Inc.'s profit margin?
ImmunityBio, Inc. (IBRX) keeps -598.56% of revenue as net profit after every cost, including tax and interest.